Bioxytran, Inc. (BIXT)
- Previous Close
0.1350 - Open
0.1397 - Bid --
- Ask --
- Day's Range
0.1300 - 0.1397 - 52 Week Range
0.0710 - 0.5351 - Volume
23,601 - Avg. Volume
105,495 - Market Cap (intraday)
22.745M - Beta (5Y Monthly) -0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
www.bioxytraninc.comRecent News: BIXT
Performance Overview: BIXT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIXT
Valuation Measures
Market Cap
23.62M
Enterprise Value
24.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1,344.96%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.3M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
10.02k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.95M
Company Insights: BIXT
BIXT does not have Company Insights